University of California - Los Angeles
Welcome,         Profile    Billing    Logout  
 78 Trials 
173 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Dobkin, Bruce
NCT02093624: A Phase II Trial of Rituximab In Myasthenia Gravis

Not yet recruiting
2
50
US
Rituximab, Placebo
Yale University
Myasthenia Gravis
05/17
12/17
CAMAROS, NCT04789616: The Canadian Maraviroc Randomized Controlled Trial To Augment Rehabilitation Outcomes After Stroke

Recruiting
2
120
Canada
Maraviroc, Celsentri, Exercise Program, Placebo, "Sugar" Pill, Activity Sensor, Motor Learning
University of Calgary, University Health Network, Toronto, University of California, Los Angeles, Sunnybrook Health Sciences Centre, University of British Columbia, Memorial University of Newfoundland, Dalhousie University, Parkwood Hospital, London, Ontario, Riverview Health Centre Foundation, The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
Stroke
12/25
12/25
Carlo, Waldemar A
NCT06518603: Caffeine Citrate in Preterm Infants At Risk of Apnea in Zambia

Not yet recruiting
4
340
RoW
Caffeine citrate 20mg/kg/day, Placebo-Sterile water 1ml/kg/day
University of Alabama at Birmingham, University Teaching Hospital, Lusaka, Zambia, Centre for Infectious Disease Research in Zambia
Premature Infant Disease, Apnea of Prematurity, Development, Infant
12/25
11/26
NCT01702805: Transfusion of Prematures Trial

Active, not recruiting
3
1824
US
Liberal Cell Transfusion, Restricted red cell transfusion
NICHD Neonatal Research Network, National Heart, Lung, and Blood Institute (NHLBI), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Infant, Newborn, Diseases, Infant, Extremely Low Birth Weight, Infant, Small for Gestational Age, Bronchopulmonary Dysplasia (BPD), Anemia
01/20
08/25
NCT01353313: Hydrocortisone for BPD

Active, not recruiting
3
800
US
Hydrocortisone, Placebo
NICHD Neonatal Research Network, National Center for Research Resources (NCRR), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Heart, Lung, and Blood Institute (NHLBI), National Center for Advancing Translational Sciences (NCATS)
Infant, Newborn, Infant, Small for Gestational Age, Infant, Very Low Birth Weight, Infant, Premature, Bronchopulmonary Dysplasia
09/20
01/25
MoCHA, NCT03340727: Moderately Preterm Infants With Caffeine at Home for Apnea () Trial

Terminated
3
827
US
Caffeine Citrate, Placebo
NICHD Neonatal Research Network, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Apnea of Prematurity
01/23
03/23
NCT04214834: Trial to Shorten Pharmacologic Treatment of Newborns With Neonatal Opioid Withdrawal Syndrome (NOWS)

Active, not recruiting
3
190
US
Morphine, Methadone
Advancing Clinical Trials in Neonatal Opioid Withdrawal (ACT NOW) Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Neonatal Opioid Withdrawal Syndrome
01/24
06/26
MIDAS, NCT06679855: Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial

Not yet recruiting
3
316
US
Milrinone infusion, Placebo infusion
NICHD Neonatal Research Network, National Heart, Lung, and Blood Institute (NHLBI)
Post-ligation Cardiac Syndrome
06/27
08/29
BiB, NCT04545866: The Budesonide in Babies () Trial

Active, not recruiting
3
1160
US
budesonide (Pulmicort nebulizing suspension)., Pulmicort nebulizing suspension., surfactant (poractant alfa;Curosurf), poractant alfa;Curosurf
NICHD Neonatal Research Network, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Bronchopulmonary Dysplasia (BPD), Respiratory Distress Syndrome, Prematurity; Extreme, Neonatal
09/24
12/26
NCT03456336: Management of the PDA Trial

Active, not recruiting
3
836
US
Active Treatment, Expectant Management
NICHD Neonatal Research Network, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Infant, Premature, Patent Ductus Arteriosus, Infant, Newborn, Diseases, Patent Ductus Arteriosus After Premature Birth
04/25
05/27
MIDAS, NCT03231735: Mid and Standard Frequency Ventilation in Infants With Respiratory Distress Syndrome

Completed
2/3
60
US
Mid frequency ventilation, Standard frequency ventilation
University of Alabama at Birmingham, University of South Alabama
Ventilator-Induced Lung Injury, Respiratory Distress Syndrome, Bronchopulmonary Dysplasia, Preterm Infant
11/21
10/24
NCT03779711: Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Repair of Hypoplastic Left Heart Syndrome

Active, not recruiting
2b
95
US
Autologous (self) mononuclear cells derived from umbilical cord blood, Stage II Surgical repair
Timothy J Nelson, MD, PhD, University of Oklahoma, Children's Hospital of Philadelphia, Children's Hospital Los Angeles, Children's Hospital Colorado, Children's Hospitals and Clinics of Minnesota, Ochsner Health System, Children's of Alabama, Children's Hospital Medical Center, Cincinnati
Hypoplastic Left Heart Syndrome
05/22
02/26
NCT02951130: Milrinone in Congenital Diaphragmatic Hernia

Active, not recruiting
2
66
US
Milrinone, Milrinone Lactate Injection, Primacor, Placebo (5% Dextrose), D5W
NICHD Neonatal Research Network, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Congenital Diaphragmatic Hernia, Persistent Pulmonary Hypertension of the Newborn, Hypoxemic Respiratory Failure, Pulmonary Hypoplasia
09/24
03/25
PRISM, NCT06377098: Intrapartum Sildenafil in Laboring Mothers

Not yet recruiting
2
1000
RoW
Sildenafil 50 mg Oral Tablet, Revatio, Sildenafil, Placebo Oral Tablet
University of Alabama at Birmingham, University Teaching Hospital, Lusaka, Zambia, Egerton University, Cameroon Baptist Convention Health
Neonatal Asphyxia, Intrapartum Fetal Distress, Development, Infant, Intrapartum Asphyxia
08/26
09/28
NCT06522854: Oral Sildenafil Citrate to Improve Maternal and Neonatal Outcomes in Low-resource Settings

Not yet recruiting
2
2000
RoW
Sildenafil 50 mg Oral Tablet, Revatio, Placebo Oral Tablet
University of Alabama at Birmingham, University of Lagos, Nigeria, Ladoke Akintola University of Technology Teaching Hospital, Ogbomoso, Lagos State University, National Health and Medical Research Council, Australia, Mater Medical Research Institute, The University of Queensland
Intrapartum Fetal Distress, Neonatal Asphyxia, Intrapartum Asphyxia, Instrumental Delivery; Affecting Fetus
05/26
11/26
NCT04907526: Intramyocardial Injection of Autologous UCB-MNC During Fontan Surgery for SRV Dependent CHD

Active, not recruiting
1
30
US
Autologous mononuclear cells
Timothy J Nelson, MD, PhD, Mayo Clinic, University of Oklahoma, Children's Hospital of Philadelphia, Children's Hospital Los Angeles, Children's Hospitals and Clinics of Minnesota, Children's Hospital Colorado, Ochsner Health System, Children's of Alabama, Children's Hospital Medical Center, Cincinnati, The Hospital for Sick Children
Congenital Heart Disease, SRV Dependent
05/23
06/25
NCT05403684: Impact of Hindmilk on Weight Gain Among Moderate to Very Preterm Infants in Zambia

Completed
N/A
214
RoW
High-volume breastmilk
University of Alabama at Birmingham, Centre for Infectious Disease Research in Zambia, Chiesi Foundation
Postnatal Growth Restriction
12/22
02/23
COCO, NCT04792099: CPAP Or Nasal Cannula Oxygen for Preterm Infants: A Randomized Controlled Trial

Completed
N/A
38
US
Continuous positive airway pressure, CPAP, Nasal Cannula, NC
University of Alabama at Birmingham
Infant, Newborn, Disease, Hypoxia, Respiratory Distress Syndrome, Bronchopulmonary Dysplasia
03/23
03/23
MNH, NCT01073475: Maternal Newborn Health Registry

Recruiting
N/A
950000
US, RoW
There is no intervention associated with the parent MNHR study. For the MNHR COVID sub-study, participants will be asked to provide a blood specimen at or near delivery.
NICHD Global Network for Women's and Children's Health
Pregnancy Outcome Trends in Low-resource Geographic Areas
01/25
01/25
NCT01604317: Evaluation of Use of Plastic Bags to Prevent Neonatal Hypothermia-Part I

Active, not recruiting
N/A
182
RoW
Resuscitation-torso plastic bag, Resuscitation-partial-head plastic bag
University of Alabama at Birmingham, Children's Health System, Alabama
Hypothermia, Immature Newborn
08/25
08/25
IMPACT, NCT06335524: Infant-Maternal Partnership and Cognitive Training Study for Preterm Infants

Recruiting
N/A
188
US
Finger puppet, Bookworm reading intervention training and routine EDI care.
University of Alabama at Birmingham
Child Development, Infant Development, Infant, Premature, Diseases
08/26
08/28
NCT03927833: Cycled Phototherapy

Recruiting
N/A
1700
US
Phototherapy lights
NICHD Neonatal Research Network, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Hyper Bilirubinemia, Premature Infant
07/25
07/25
NPC-QIC, NCT02852031: National Collaborative to Improve Care of Children With Complex Congenital Heart Disease

Recruiting
N/A
1000
Europe, Canada, US
Collaborative Learning Network
Children's Hospital Medical Center, Cincinnati
Hypoplastic Left Heart Syndrome (HLHS)
05/26
05/28
NCT00063063: Generic Database of Very Low Birth Weight Infants

Recruiting
N/A
80000
US
NICHD Neonatal Research Network, National Center for Research Resources (NCRR), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
03/30
03/30
NCT00009633: Follow-up Visit of High Risk Infants

Recruiting
N/A
68000
US
NICHD Neonatal Research Network, National Center for Research Resources (NCRR), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
03/30
03/30
Shoptaw, Steve
STAR-OM, NCT04706624: Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics

Active, not recruiting
N/A
667
RoW
High intensity contingency management, Low intensity contingency management, SMS reminders, Matrix only, Matrix + Contingency management
Hanoi Medical University, University of California, Los Angeles, University of Medicine and Pharmacy at Ho Chi Minh City
Methamphetamine Abuse, Opioid-use Disorder, HIV Seropositivity
06/24
03/25
Pantuck, Allan
NCT04305925: Focal Laser Ablation of Prostate Cancer

Active, not recruiting
1
10
US
Focal Laser Ablation
Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI)
Prostate Cancer
01/23
10/25
IRONMAN, NCT03151629: International Registry for Men With Advanced Prostate Cancer

Recruiting
N/A
5000
Europe, Canada, US, RoW
Standard of Care
Prostate Cancer Clinical Trials Consortium
Prostate Cancer
01/31
01/32
Perlman, Susan
NEAT, NCT06193200: Evaluate the Neurological Effects of EryDex on Subjects With A-T

Recruiting
3
106
Europe, US
Dexamethasone sodium phosphate, DSP, Placebo
Quince Therapeutics S.p.A., Biotrial
Ataxia Telangiectasia
08/25
09/25
OLE_NEAT, NCT06664853: Open-Label Extension of EryDex Study IEDAT-04-2022

Recruiting
3
106
Europe, US
Dexamethasone sodium phosphate
Quince Therapeutics S.p.A., Biotrial
Ataxia Telangiectasia
11/26
11/26
STRIDES, NCT05490563: - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia

Terminated
2/3
23
Europe, US, RoW
SLS-005, Placebo
Seelos Therapeutics, Inc.
Spinocerebellar Ataxia Type 3
11/23
11/23
NCT03759678 / 2018-004407-39: N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T)

Recruiting
2
39
Europe, US
IB1001, N-Acetyl-L-Leucine
IntraBio Inc
Ataxia Telangiectasia, Louis Bar Syndrome
12/24
03/25
NCT05526391 / 2022-000336-28: A Study of TAK-341 in Treatment of Multiple System Atrophy

Active, not recruiting
2
159
Europe, Japan, US
TAK-341, MEDI1341, Placebo
Takeda, AstraZeneca
Multiple System Atrophy
07/25
07/25
NCT05923866: A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

Recruiting
2
80
US
ONO-2808, Placebo
Ono Pharmaceutical Co. Ltd
Multiple System Atrophy (MSA)
08/25
08/25
NCT03487367: Clinical Trial Readiness for SCA1 and SCA3

Active, not recruiting
N/A
200
US
The Methodist Hospital Research Institute, University of Michigan, University of Minnesota, University of Utah, University of California, Los Angeles, University of Chicago, University of South Florida, Harvard University, Johns Hopkins University, University of Florida, Columbia University, Emory University, University of California, San Francisco, University of Alabama at Birmingham, University of Colorado, Denver, University of Rochester, Stanford University, Northwestern University, German Center for Neurodegenerative Diseases (DZNE), Institut de Recherche sur la Moelle épinière et l'Encéphale, University of Pennsylvania, Ohio State University, University of Iowa
Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia 3
12/23
12/23
NCT06445712: Examining the Role of Pain in the Link Between Early Childhood Adversity and Psychopathology

Recruiting
N/A
40
US
Parental Support Cold Pressor Task
Washington University School of Medicine, National Center for Advancing Translational Sciences (NCATS)
Child Development
04/25
04/25
NCT01060371: Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias

Recruiting
N/A
800
US
All Participants
University of Florida, National Ataxia Foundation, University of California, Los Angeles
Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6
05/24
05/24
IDEA, NCT04268147: Instrumented Data Exchange for Ataxia Study

Completed
N/A
128
US
University of Chicago, Pfizer, Biogen, APDM Wearable Technologies
Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Friedreich Ataxia
04/24
06/24
NCT06623890: A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it for the First Time

Recruiting
N/A
300
Europe, US, RoW
Omaveloxolone, SKYCLARYS, BIIB141
Reata, a wholly owned subsidiary of Biogen
Friedreich Ataxia
10/29
10/29
FA-COMS, NCT03090789: FA Clinical Outcome Measures

Active, not recruiting
N/A
2000
Canada, US, RoW
Friedreich's Ataxia Research Alliance, University of Rochester, Children's Hospital of Philadelphia
Friedreich Ataxia, Neuro-Degenerative Disease
01/30
01/30
UNIFAI, NCT06016946: Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study

Recruiting
N/A
3000
Europe, Canada, US, RoW
Friedreich's Ataxia Research Alliance
Friedreich Ataxia
01/48
01/48
NCT01574053: Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

Recruiting
N/A
35000
Europe, Canada, US, RoW
CHDI Foundation, Inc.
Huntington's Disease
01/62
01/62
Hurvitz, Sara
ENABLAR-2, NCT05065411: Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer

Terminated
3
5
US
Enobosarm & Abemaciclib Combo, VERU-024, Verzenio, non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant, exemestane, fulvestrant, exemestane plus everolimus
Veru Inc.
Metastatic Breast Cancer
10/23
01/24
postMONARCH, NCT05169567 / 2021-002301-10: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Active, not recruiting
3
368
Europe, US, RoW
Abemaciclib, Fulvestrant, Placebo
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasm, Neoplasm Metastasis
02/24
02/26
FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects

Recruiting
3
750
Europe, US
Placebo, GLSI-100
Greenwich LifeSciences, Inc.
Breast Cancer
12/26
12/26
NCT02668939: Presurgical Treatment With Single-Agent Trastuzumab or Lapatinib or the Combination of Trastuzumab and Lapatinib, Followed by Six Cycles of Docetaxel & Carboplatin With Trastuzumab or Lapatinib or the Combination of Trastuzumab and Lapatinib in Patients With HER2/+ Operable Breast Cancer

Active, not recruiting
2
140
US
TCH, Trastuzumab, Docetaxel, carboplatin, TCTy, Lapatinib, docetaxel, TCHTy, lapatinib
Translational Oncology Research International, Sanofi, GlaxoSmithKline
Adenocarcinoma of the Breast, Tumor HER2/Neu Positive
01/16
 
NCT05113966: Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Checkmark Data from P2 trial for locally advanced or metastatic TNBC
Nov 2022 - Nov 2022: Data from P2 trial for locally advanced or metastatic TNBC
Checkmark Presentation of data from P2 trial for locally advanced or metastatic TNBC
Nov 2022 - Nov 2022: Presentation of data from P2 trial for locally advanced or metastatic TNBC
Terminated
2
30
US
Trilaciclib, G1T28, CDK 4/6 inhibitor, Sacituzumab Govitecan-hziy, Trodelvy, IMMU-132
G1 Therapeutics, Inc.
Triple Negative Breast Cancer
11/23
06/24
HER2CLIMB-04, NCT04539938: A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

Active, not recruiting
2
70
US
tucatinib, TUKYSA, ARRY-380, ONT-380, trastuzumab deruxtecan, T-DXd, Enhertu, DS-8201
Seagen Inc.
HER2 Positive Breast Cancer
07/24
10/25
TELESCOPE, NCT06604858: Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer

Not yet recruiting
2
30
NA
Pembrolizumab, Carboplatin, Paclitaxel
MedSIR, Merk Sharp & Dohme España S.A.
Breast Cancer, Triple Negative Breast Cancer
10/26
10/26
TRIO-US B-12 TALENT, NCT04553770: Trastuzumab Deruxtecan Alone or in Combination with Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

Checkmark Presentation of data from TALENT trial for HER2 Low, HR+ breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from TALENT trial for HER2 Low, HR+ breast cancer at SABCS 2022
Recruiting
2
88
US
Anastrozole, Anastrazole, Arimidex, ICI D1033, ICI-D1033, ZD-1033, Therapeutic Conventional Surgery, Trastuzumab Deruxtecan, DS-8201, DS-8201a, Enhertu, Fam-trastuzumab Deruxtecan-nxki, WHO 10516
Jonsson Comprehensive Cancer Center, Translational Research in Oncology-U.S, Daiichi Sankyo Co., Ltd.
Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
09/25
09/25
ZWI-ZW25-204, NCT05027139: A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer

Active, not recruiting
1/2
52
US
Zanidatamab, ZW25, JZP598, Evorpacept, ALX148
Jazz Pharmaceuticals, ALX Oncology Inc.
HER2-expressing Cancers
04/25
09/25
NCT05511844: Study of ORM-5029 in Subjects with HER2-Expressing Advanced Solid Tumors

Active, not recruiting
1
87
US
ORM-5029
Orum Therapeutics USA, Inc.
HER2-positive Breast Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, HER2 Gene Mutation
04/25
10/25
Belperio, John
ELEVAATE, NCT05856331: Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema

Active, not recruiting
2
99
Europe, US, RoW
SAR447537, Zemaira, Respreeza
Sanofi
Alpha 1-Antitrypsin Deficiency, Emphysema
08/25
10/25
IPF-PRO, NCT01915511: Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry

Checkmark
Oct 2015 - Oct 2015: 
Recruiting
N/A
3000
US
Duke University, Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
01/28
01/28
Jung, Brian
A1BC, NCT05297812: Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease

Active, not recruiting
N/A
286
US
Columbia University, Alpha-1 Foundation, National Heart, Lung, and Blood Institute (NHLBI)
Alpha 1-Antitrypsin Deficiency, Genetic Disease
01/27
01/27
Dunn, James
ADVISE, NCT03828019: Adalimumab vs. Conventional Immunosuppression for Uveitis Trial

Active, not recruiting
3
222
Europe, Canada, US, RoW
Adalimumab (ADA), Adalimumab, Humira, Conventional immunosuppression (CON), Azathioprine, Imuran , Cyclosporine, Methotrexate, Rheumatrex, Mycophenolate, CellCept, Cyclosporine, Sandimmune, Neoral, Tacrolimus, Prograf
JHSPH Center for Clinical Trials
Uveitis
04/24
09/24
Grill, Joshua
NCT02093624: A Phase II Trial of Rituximab In Myasthenia Gravis

Not yet recruiting
2
50
US
Rituximab, Placebo
Yale University
Myasthenia Gravis
05/17
12/17
TRC-PAD, NCT04004767: Program: In-Clinic Trial-Ready Cohort

Completed
N/A
220
US
University of Southern California, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute, Alzheimer's Clinical Trials Consortium, Brigham and Women's Hospital, Cleveland Clinic Lou Ruvo Center for Brain Health
Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease, Dementia
04/24
04/24
Bordelon, Yvette
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy

Active, not recruiting
2/3
110
Europe, US
AMX0035, Placebo
Amylyx Pharmaceuticals Inc.
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
04/26
11/29
Shieh, Perry
EXPEDITION, NCT05967351: A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study

Enrolling by invitation
3
400
Europe, Japan, US, RoW
delandistrogene moxeparvovec, SRP-9001, delandistrogene moxeparvovec-rokl, ELEVIDYS
Sarepta Therapeutics, Inc., Hoffmann-La Roche
Duchenne Muscular Dystrophy
11/30
11/30
REACH CDM, NCT03692312: Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy

Completed
2/3
56
Europe, Canada, US, RoW
Tideglusib, Placebo
AMO Pharma Limited
Congenital Myotonic Dystrophy
04/23
04/23
REACH CDM X, NCT05004129: Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy

Recruiting
2/3
76
Canada, US, RoW
Tideglusib
AMO Pharma Limited
Congenital Myotonic Dystrophy
03/25
03/25
NCT05721573: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Active, not recruiting
2/3
231
Europe, Canada, US, RoW
ABC008
Abcuro, Inc., Syneos Health
Inclusion Body Myositis
11/25
12/25
NCT02093624: A Phase II Trial of Rituximab In Myasthenia Gravis

Not yet recruiting
2
50
US
Rituximab, Placebo
Yale University
Myasthenia Gravis
05/17
12/17
MAGiNE, NCT04231266: Multi-Center Study of ManNAc for GNE Myopathy

Active, not recruiting
2
54
US
ManNAc, N-acetyl-D-mannosamine monohydrate, Placebo
Leadiant Biosciences, Inc., Brigham and Women's Hospital, National Human Genome Research Institute (NHGRI), National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH (NIAMS and NIND) as part of NeuroNext
GNE Myopathy
05/25
10/25
NCT06138639: A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)

Recruiting
1/2
43
Canada, US
SGT-003
Solid Biosciences Inc.
Duchenne Muscular Dystrophy
05/27
05/31
DELIVER, NCT05524883 / 2021-005478-24: Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

Recruiting
1/2
88
Europe, Canada, US, RoW
DYNE-251, Placebo
Dyne Therapeutics, Dyne Therapeutics, Inc
Duchenne Muscular Dystrophy (DMD)
11/29
11/29
EAP-001, NCT02189720: Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome

No Longer Available
N/A
US
Amifampridine Phosphate, 3,4-Diaminopyridine Phosphate, 3,4 DAP, Firdapse®
Catalyst Pharmaceuticals, Inc.
Congenital Myasthenic Syndrome, Lambert-Eaton Myasthenic Syndrome, Nystagmus, Acquired
 
 
MOVE FSHD, NCT04635891: Motor Outcomes to Validate Evaluations in FSHD

Recruiting
N/A
450
Europe, Canada, US
University of Kansas Medical Center, FSHD Society, Inc., Friends Research Institute, Inc., University of Rochester, University of Nevada, Reno, FSHD Canada, Avidity Biosciences, Inc., AMRA Medical, Seattle Children's Hospital, Dyne Therapeutics, Hoffmann-La Roche
FSHD
12/26
01/27
INSPIRE-IBM, NCT05046821: Sporadic Inclusion Body Myositis Natural History Study

Active, not recruiting
N/A
150
US
University of California, Irvine, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Sporadic Inclusion Body Myositis, Inclusion Body Myositis
01/26
01/26
NCT03981575: Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)

Recruiting
N/A
700
Europe, Canada, US, RoW
Virginia Commonwealth University, University of Rochester, Stanford University, Ohio State University, University of Florida, University of Iowa, Ludwig-Maximilians - University of Munich, Fondazione Serena Onlus - Centro Clinico NeMO Milano, The Methodist Hospital Research Institute, Radboud University Medical Center, University College London Hospitals, University of California, Los Angeles
Myotonic Dystrophy 1, DM1
10/26
12/26
ASPIRE-DM1, NCT05224778: DMCRN-02-001: Assessing Pediatric Endpoints in DM1

Recruiting
N/A
50
Europe, US
Virginia Commonwealth University
Congenital Myotonic Dystrophy, Childhood Myotonic Dystrophy, CDM, CHDM
10/26
12/26
NCT04174157: Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)

Recruiting
N/A
700
Europe, Japan, US, RoW
Prospective observational registry, Zolgensma
Novartis Pharmaceuticals, United BioSource, LLC
Spinal Muscular Atrophy (SMA)
06/38
06/38
Ray, Lara
NCT03594435: Ibudilast for the Treatment of Alcohol Use Disorder

Completed
2
102
US
Ibudilast, Pinatos, MN-166, Placebo oral capsule, Sugar Pill
University of California, Los Angeles, National Institute on Alcohol Abuse and Alcoholism (NIAAA), MediciNova
Alcohol Use Disorder
04/23
04/23
NCT03878316: Intranasal Oxytocin for the Treatment of Alcohol Use Disorder

Completed
2
100
US
Instranasal Oxytocin
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alcohol Use Disorder, Alcohol Misuse
10/23
10/23
NCT06494891: Motivation for IV Alcohol Self-Administration in Humans

Recruiting
2
210
US
Intravenous Alcohol
University of California, Los Angeles
Alcohol Use Disorder
04/27
06/27
NCT04310423: An Inflammatory Challenge Using Endotoxin

Completed
2
20
US
Placebo, Saline (0.9%), Endotoxin, Escherichia coli
University of California, Los Angeles
Alcohol Use Disorder, Inflammatory Response, Craving, Depressed Mood
11/23
11/23
SUV, NCT06679062: Suvorexant for Treatment of AUD and PTSD

Not yet recruiting
2
76
US
Suvorexant, SUV, Dual orexin receptor antagonist, Placebo
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance, University of California, Los Angeles, The University of Texas Health Science Center, Houston
Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD), Insomnia
06/26
06/26
AFA-281-304, NCT06710431: A Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use Disorder

Not yet recruiting
2
36
US
AFA-281
Afasci Inc
Alcohol Abuse, Alcohol Abuse/addiction, Anxiety, Pain Threshold, Depression Disorders, Sleep Disorder
06/27
12/27
Thompson, Rachel
NCT04074265: Peri-operative Use of a Pain Injection in Pediatric Patients With Cerebral Palsy

Completed
4
34
US
Ropivacaine injection, ropivacaine, ketorolac, epinephrine, normal saline
University of California, Los Angeles, Northwestern University
Cerebral Palsy, Hip Dysplasia, Pain, Postoperative
03/23
04/23
NCT06189781: Pain Injection Versus Epidural Anesthesia for Hip Surgery in Pediatric Patients With Cerebral Palsy

Recruiting
4
90
US
Ropivacaine injection, Bupivacaine, lidocaine, ropivacaine
University of California, Los Angeles, Northwestern University
Cerebral Palsy, Hip Dysplasia, Pain, Postoperative
12/26
06/27
NCT03759028: Supracondylar Post-Operative Pain Study

Recruiting
4
90
US
Ibuprofen, Advil, Motrin, Oxycodone, roxicodone, Acetaminophen, Tylenol, Paracetamol
University of California, Los Angeles
Supracondylar Humerus Fracture
12/24
06/25
NCT04074252: Mobility Impairment in the Northern Region of Malawi

Withdrawn
N/A
193
US
Lofstrand Crutches, Axillary Crutches
University of California, Los Angeles, Project Malawi
Mobility Limitation
07/22
07/22
NCT06376448: An Observational Study Using Novel Questionnaire to Characterize Cough Phenotypes in Patients With Chronic Cough

Recruiting
N/A
60
Europe
Hull University Teaching Hospitals NHS Trust
Chronic Cough
10/24
02/25
NCT05660096: Pediatric Neural Sleeve Validation

Withdrawn
N/A
30
US
Cionic Neural Sleeve NS-100, External functional neuromuscular stimulator
University of California, Los Angeles, Cionic, Inc.
Cerebral Palsy
12/26
12/26
Kafaja, Suzanne
NCT02541955: Use of Acthar in Rheumatoid Arthritis (RA) Related Flares

Recruiting
4
40
US
Acthar, Repository corticotropin injection
Veena Ranganath, MD, MS
Rheumatoid Arthritis (RA)
12/24
12/25
BLISSc-ILD, NCT05878717: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Hourglass Jan 2021 - Jun 2021 : Submission in combination with rituximab for SLE
Recruiting
2/3
300
Europe, Japan, US, RoW
Belimumab, BENLYSTA™, GSK1550188, LymphoStat-B™, BENLYSTATM, GSK1550188, LymphoStat-B™, Placebo
GlaxoSmithKline
Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
07/27
07/27
NCT02682511: Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

Recruiting
2
34
US, RoW
Oral Ifetroban, Ifetroban, Oral Placebo
Cumberland Pharmaceuticals
Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited, Sclerosis, Progressive Systemic, Skin Diseases, Connective Tissue Diseases, Pathologic Processes, Autoimmune Diseases
12/25
12/25
BRAVOS, NCT03222492: Brentuximab Vedotin for Systemic Sclerosis

Completed
1/2
17
US
Brentuximab Vedotin, Adcetris®, Placebo, Placebo for brentuximab vedotin
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), Seagen Inc., PPD, Rho Federal Systems Division, Inc.
Diffuse Cutaneous Systemic Sclerosis, Scleroderma, dcSSc
04/23
04/23
Bordelon, Yvette M
NCT01574053: Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

Recruiting
N/A
35000
Europe, Canada, US, RoW
CHDI Foundation, Inc.
Huntington's Disease
01/62
01/62
Devaskar, Uday
NCT01702805: Transfusion of Prematures Trial

Active, not recruiting
3
1824
US
Liberal Cell Transfusion, Restricted red cell transfusion
NICHD Neonatal Research Network, National Heart, Lung, and Blood Institute (NHLBI), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Infant, Newborn, Diseases, Infant, Extremely Low Birth Weight, Infant, Small for Gestational Age, Bronchopulmonary Dysplasia (BPD), Anemia
01/20
08/25
NCT01353313: Hydrocortisone for BPD

Active, not recruiting
3
800
US
Hydrocortisone, Placebo
NICHD Neonatal Research Network, National Center for Research Resources (NCRR), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Heart, Lung, and Blood Institute (NHLBI), National Center for Advancing Translational Sciences (NCATS)
Infant, Newborn, Infant, Small for Gestational Age, Infant, Very Low Birth Weight, Infant, Premature, Bronchopulmonary Dysplasia
09/20
01/25
NCT00009633: Follow-up Visit of High Risk Infants

Recruiting
N/A
68000
US
NICHD Neonatal Research Network, National Center for Research Resources (NCRR), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
03/30
03/30
Veeraraghavan, Srihari
TETON, NCT04708782: Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Hourglass May 2024 - Aug 2024 : Topline data for IPF
Hourglass Jan 2023 - Mar 2023 : Enrollment completion of TETON trial for IPF
Recruiting
3
576
Canada, US
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
06/25
06/25
MILED, NCT03150914: Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial

Active, not recruiting
3
60
US
Sirolimus, Rapamycin
University of Cincinnati, National Heart, Lung, and Blood Institute (NHLBI), National Center for Advancing Translational Sciences (NCATS), The LAM Foundation
LAM, Lymphangioleiomyomatosis
06/25
06/25
TETON-PPF, NCT05943535: Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis

Recruiting
3
698
Canada, US, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
11/27
11/27
CONQUEST, NCT06195072: Platform Clinical Study for Conquering Scleroderma

Recruiting
2
400
US
Amlitelimab, BI 1015550, Placebo
Scleroderma Research Foundation, Inc., Sanofi, Boehringer Ingelheim
Interstitial Lung Disease Due to Systemic Disease, Scleroderma
11/26
11/26
PHINDER, NCT05776225: Pulmonary Hypertension Screening in Patients with Interstitial Lung Disease for Earlier Detection

Recruiting
N/A
200
US
Right heart catheterization (RHC)
United Therapeutics
Interstitial Lung Disease, Pulmonary Hypertension
05/25
06/25
IPF-PRO, NCT01915511: Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry

Checkmark
Oct 2015 - Oct 2015: 
Recruiting
N/A
3000
US
Duke University, Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
01/28
01/28
Purdy, Isabell
NCT00009633: Follow-up Visit of High Risk Infants

Recruiting
N/A
68000
US
NICHD Neonatal Research Network, National Center for Research Resources (NCRR), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
03/30
03/30
 

Download Options